Characteristics of the study population of included studies
| Study | Size | Age | Female (%) | RF+ (%) | Disease duration | DAS28 at baseline |
|---|---|---|---|---|---|---|
| Blanchais et al38 | 26 | 56.6 (9.5) | NR | NR | 16.6 (10) y | NR |
| Bossert et al39 | 200 | 57 (11.5) | 75.5 | 78 | 13 (8.3) y | 3.61 (1.43) |
| Castréjon et al40 | 39 | 56.8 (13.9) | 90 | NR | 3.5 (NR) y | NR |
| Castréjon et al41 | 720 | 48.2 (12.4) | 76.2 | NR | 4.8 (2.9–7.0)* m | 5.1 (1.3) |
| Choy et al9 | 322 | 60.3 (23–87)† | 76 | 81 | 9.13 (0–48)† y | NR |
| Fransen et al42 | 92 | 52 (13) | 83 | 87 | 9 (4–14)* y | NR |
| Fransen et al20 | 584 | 59 (12) | 72 | 69 | 8 (3–15)* y | 4.3 (1.4) |
| Fujiwara et al43 | 250 | 59.3 (14) | 78.4 | NR | 10.35 (9.83) y | NR |
| Harrington44 | 185 | 63 (22–88)† | NR | NR | 18 (2–51)‡ y | NR |
| Heegaard et al45 | 30 | 60 (15) | 77 | 70 | 15 (6)y | 3.5 (1.0)§ |
| Houssien et al10 | 100 | 57.7 (12.2) | 78 | NR | 11.5 (8.3) y | 4.24 (1.3) |
| Janta et al11 | 69 | 60.12 (13.16) | 76.8 | NR | 11.9 (8.6) y | 2.55 (1.08) |
| Kavanaugh et al12 | 218 | 54.3 (21–88)† | 81.7 | NR | 8.5 (NR) y | 5.4 (1.3) |
| 229 | 54.7 (19–82)† | 76.9 | 7.2 (NR) y | 5.0 (1.3)§ | ||
| Leeb et al21 | 169 | 57 (19–78)† | 79.8 | 50 | 7.2 (0.2–46)† y | 3.51 (0.28–6.67)† |
| Leeb et al22 | 108 | 59.5 (24–87)‡ | 77.7 | 54 | NR | 2.95 (0.43–6.24)‡ |
| Pincus46 | 63 | 58.5 (19.7)* | ref | ref | 3.5 (8.8)* y | ref |
| 30 | 54.6 (20.9)* | 2.9 (8.9)* y | ||||
| Pincus et al23 | 557 | ref | ref | ref | ref | 6.82 (NR)/6.83(NR) |
| 278 | 6.89 (NR)/6.88(NR) | |||||
| Pincus et al47 | 1384 | ref | ref | ref | ref | ref |
| Pincus et al48 | 982 | ref | ref | ref | ref | ref |
| Pincus et al49 | 557 | ref | ref | ref | ref | ref |
| 227 | ||||||
| Pincus et al50 | Ref | ref | ref | ref | ref | ref |
| Pincus et al51 | 285 | 57.4 (14.6) | 73 | NR | 9.7 (9.0) y | 3.4 (1.7) |
| Pincus et al52 | 200 | 53.4 (16.2) | 81 | NR | 11.6 (10.8) y | 3.7 (1.5) |
| Riazzoli et al13 | 47 | 50 (13) | 79 | 86 | 9.4 (8.6) y | 5.4 (1.2) |
| Rintelen et al24 | 392 | 61 (20–87)‡ | 82.1 | 59.4 | 62 (3.545)‡ m | 3.26 (0.49–8.09)‡ |
| Rintelen et al53 | 705 | 62.7 (13.4) | 75.9 | 54.4 | 97.3 (98.0) m | 3.31 (1.37) |
| Salaffi et al54 | 191 | 56.6 (12.2) | 82.7 | NR | 5.1 (5.5) y | 6.02 (1.15) |
| Salaffi et al55 | 196 | 56.7 (12.1) | 83.1 | 78 | 5.1 (5.9) y | 3.94 (2.03) |
| 247 | 58.1 (11.2) | 80.1 | 76 | 6.2 (6.6) y | ||
| Singh et al56 | 200 | 42.2 (NR) | 83 | NR | 4.9 (NR) y | 5.2 (1.6) |
| Stucki et al57 | 55 | 60.0 (14.6) | 62 | NR | 5.1 (1.3–10.7)* y | NR |
| Sullivan et al58 | 740 | 57 (13.7) | 83 | 63.8 | 14.3 (12.3) y | 4.05 (1.5)§ |
| Uhlig et al59 | 28 | 61.1 (6.2) | 64 | 64 | 16.6 (10.4) y | 3.12 (1.27) |
| Veehof et al25 | 191 | 54.5 (13.3) | 71 | NR | 7.0 (3–17)* y | 5.42 (1.07) |
| Wolfe et al26 | 9078 | 62.2 (12.6) | 78.2 | NR | 16.2 (10.9) y | NR |
*Median(IQR): Values are mean (standard deviation) unless otherwise indicated.
†Mean (range).
‡Median (range).
§DAS28-CRP.
CRP, C-reactive protein; DAS28, Disease Activity Score with 28-Joint Counts; m, months; NR, not reported; ref, reference to results in earlier publication; RF+, rheumatoid factor positive; y, years.